The study, conducted independently and not sponsored by MELA Sciences, Inc. had an initial cohort of 166 pigmented lesions on 30 patients were identified as suspicious by visual inspection and dermoscopy. 64 of those lesions were identified for biopsy and 102 were selected for continued observation.

The report stated, "The results showed 61% of the clinically suspicious pigmented lesions in an at-risk population were deferred from biopsy, indicating that MelaFind analysis may prevent overly aggressive biopsy decisions. There may also be an overall improvement in biopsy risk."

Rose Crane, MELA Sciences President and CEO said, "Using the MelaFind system, doctors at this hospital achieved measurable success that adds to our growing body of evidence showing the MelaFind system can reduce health care costs when treating what is today one of the fastest growing cancers. There are a number of challenges in detecting melanoma and the doctors at this institution using MelaFind exemplify the positive shift in healthcare outcomes that can be achieved when innovative technology is implemented and its progress is quantified."

To learn more go to: www.melafind.com.